article thumbnail

GPhC November pass rate drops again to 2022 levels

The Pharmacist

This brings the pass rates back down almost to November 2022 levels of 56%, following a 10% rise to 66% in November 2023. And it comes as summer pass rates have seen a steady decline […] The post GPhC November pass rate drops again to 2022 levels appeared first on The Pharmacist.

Diabetes 121
article thumbnail

Tranq dope (fentanyl-xylazine combination): A new horizon in opioid withdrawal treatment

ALiEM - Pharm Pearls

Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. Drug Checking Quarterly Report (Q3 2022). 2022; 06/26/2023. 2022 May;14(5). 2011 Dec;6:1-4.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

STAT+: Health tech investments are picking up steam. Here are 5 VC leaders behind the biggest recent deals

STAT

Health tech investments are showing signs of resilience following the perilous lows of 2022 and 2023: Just this past month, two startups that analysts believe might be getting ready for IPOs raised more than $100 million in late-stage funding rounds.

Diabetes 306
article thumbnail

Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends

Express Pharma

Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3 billion in 2023 and is expected to grow at a CAGR of 8.4 per cent from 2024 to 2030.

Diabetes 105
article thumbnail

AZ boasts phase 3 win for self-administered gMG drug

pharmaphorum

Skip to main content Thursday 24 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Type 1 diabetes market to reach $9.9 bn in 7MM by 2033

Express Pharma

The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in 2023 to $9.9 per cent from $2.2

Diabetes 105